9CD5

FGFR1 Kinase Domain Soak with Inhibitor TYRA-300

This is a non-PDB format compatible entry.

Summary for 9CD5

• Entry DOI: 10.2210/pdb9cd5/pdb
• Descriptor: Fibroblast growth factor receptor 1, 1,2-ETHANEDIOL, (3P)-5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-3-{6-[6-(methanesulfonyl)-2,6-diazaspiro[3.3]heptan-2-yl]pyridin-3-yl}-1H-indazole, ... (5 entities in total)
• Functional Keywords: kinase, transferase, inhibitor, cancer, achondroplasia, fgfr3, fgfr, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 2
• Total formula weight: 72710.53

Authors

Hoffman, I.H.,Nelson, K.J.,Rideout, M.C.,Frye, C.,Bensen, D.C.,Hudkins, R.L. (deposition date: 2024-06-24, release date: 2024-09-25)

• Primary citation: Hudkins, R.L.,Allen, E.,Balcer, A.,Hoffman, I.D.,Iyer, S.,Neal, M.,Nelson, K.J.,Rideout, M.,Ye, Q.,Starrett, J.H.,Patel, P.,Harris, T.,Swanson, R.V.,Bensen, D.C.; Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia.; J.Med.Chem., 2024; PubMed: 39258897; DOI: 10.1021/acs.jmedchem.4c01531

Experimental method

X-RAY DIFFRACTION (2.939 Å)